Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 5/2005

01-11-2005 | Original Article

Magnesium depletion enhances cisplatin-induced nephrotoxicity.

Authors: H. Lajer, M. Kristensen, H. H. Hansen, S. Nielsen, J. Frøkiær, L. F. Østergaard, S. Christensen, G. Daugaard, T. E. N. Jonassen

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2005

Login to get access

Abstract

Purpose: Nephrotoxicity and magnesium (Mg)-depletion are well-known side effects to cisplatin (CP) treatment. The purpose of this present study was to investigate the role of Mg on CP induced changes in renal function. CP induced renal dysfunction was achieved by treatment with CP or vehicle (2.5 mg/kg) once weekly for 3 weeks. Since the CP-induced renal damage, including tubular reabsorption defects, is most prominent within the outer medulla (OM), changes in the expression pattern of OM aquaporins and sodium transporters including the Na,K-ATPase (α-subunit), type III Na,H-exchanger (NHE3), aquaporin 1 (AQP1) and 2 (AQP2) and the Na,K,2Cl-cotransporter (NKCC2) were investigated by semi-quantitative Western blotting. Experimental design: Rats had access to either a diet with standard Mg or to a Mg-depleted diet. Cisplatin was administered to female Wistar rats once a week for 3 weeks according to four regimens: (1) Cisplatin 2.5 mg/kg body weight i.p., to rats on a diet with standard Mg, (2) Cisplatin 2.5 mg/kg body weight i.p., to rats on a diet with low Mg, (3) Isotonic NaCl 2.5 ml/kg body weight i.p., to rats on a diet with standard Mg, (4) Isotonic NaCl 2.5 ml/kg body weight i.p., to rats on a diet with low Mg. Results: CP had no effect on plasma creatinine or urea in rats with standard Mg intake, but the expression of all five transporters was significantly reduced when compared to vehicle treated rats on standard Mg-intake. Vehicle treated rats on low Mg-intake had a significant reduction in the expression of Na,K-ATPase, NHE3 and NKCC2, but unchanged expression levels of AQP1 or AQP2 when compared to standard treated controls. Forty percent of the CP-treated rats on low Mg-intake died during the experiment and the remaining animals had marked increased plasma creatinine and urea. Furthermore, the Western blot analysis revealed an almost complete disappearance of all four transporters, suggesting a dramatic synergistic effect of CP and Mg-depletion on renal function including the expression pattern of outer medullary sodium transporters and aquaporins. Conclusions: This study indicates a substantial additive effect of Mg-depletion on cisplatin induced renal toxicity as evidenced by significant changes in plasma creatinine and urea, renal failure induced mortality and loss of renal transporters. This should give cause for concern since the nephrotoxicity observed during cisplatin treatment might be substantiated by the known Mg-loss associated with cisplatin treatment especially in patients suffering from intense gastro-intestinal side effects.
Literature
1.
go back to reference Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44(2):164–172PubMed Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44(2):164–172PubMed
2.
go back to reference Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213(3):551–556PubMed Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213(3):551–556PubMed
3.
go back to reference Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54(1):19–23PubMed Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54(1):19–23PubMed
4.
go back to reference Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28(6):914–921PubMed Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH (1985) Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int 28(6):914–921PubMed
5.
go back to reference Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25(1):47–58PubMed Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25(1):47–58PubMed
6.
go back to reference Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL (1995) A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 31A(2):174–178PubMed Evans TR, Harper CL, Beveridge IG, Wastnage R, Mansi JL (1995) A randomised study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 31A(2):174–178PubMed
7.
go back to reference Lofts FJ, Evans TR, Wastnage R, Mansi JL (1996) Magnesium supplements with cisplatin chemotherapy. Eur J Cancer 32A(3):556–557PubMed Lofts FJ, Evans TR, Wastnage R, Mansi JL (1996) Magnesium supplements with cisplatin chemotherapy. Eur J Cancer 32A(3):556–557PubMed
8.
go back to reference Macaulay VM, Begent RH, Phillips ME, Newlands ES (1982) Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy. Cancer Chemother Pharmacol 9(3):179–181PubMed Macaulay VM, Begent RH, Phillips ME, Newlands ES (1982) Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy. Cancer Chemother Pharmacol 9(3):179–181PubMed
9.
go back to reference Asai T, Nakatani T, Yamanaka S, Tamada S, Kishimoto T, Tashiro K et al (2002) Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation 74(6):784–791PubMed Asai T, Nakatani T, Yamanaka S, Tamada S, Kishimoto T, Tashiro K et al (2002) Magnesium supplementation prevents experimental chronic cyclosporine a nephrotoxicity via renin-angiotensin system independent mechanism. Transplantation 74(6):784–791PubMed
10.
go back to reference Magil AB, Mavichak V, Wong NL, Quamme GA, Dirks JH, Sutton RA (1986) Long-term morphological and biochemical observations in cisplatin-induced hypomagnesemia in rats. Nephron 43(3):223–230PubMed Magil AB, Mavichak V, Wong NL, Quamme GA, Dirks JH, Sutton RA (1986) Long-term morphological and biochemical observations in cisplatin-induced hypomagnesemia in rats. Nephron 43(3):223–230PubMed
11.
go back to reference Orlowski J, Kandasamy RA (1996) Delineation of transmembrane domains of the Na+/H+ exchanger that confer sensitivity to pharmacological antagonists. J Biol Chem 271(33):19922–19927PubMed Orlowski J, Kandasamy RA (1996) Delineation of transmembrane domains of the Na+/H+ exchanger that confer sensitivity to pharmacological antagonists. J Biol Chem 271(33):19922–19927PubMed
12.
go back to reference Ecelbarger CA, Terris J, Hoyer JR, Nielsen S, Wade JB, Knepper MA (1996) Localization and regulation of the rat renal Na(+)-K(+)-2Cl- cotransporter, BSC-1. Am J Physiol 271(3 Pt 2):F619–F628PubMed Ecelbarger CA, Terris J, Hoyer JR, Nielsen S, Wade JB, Knepper MA (1996) Localization and regulation of the rat renal Na(+)-K(+)-2Cl- cotransporter, BSC-1. Am J Physiol 271(3 Pt 2):F619–F628PubMed
13.
go back to reference Nielsen S, Smith BL, Christensen EI, Knepper MA, Agre P (1993) CHIP28 water channels are localized in constitutively water-permeable segments of the nephron. J Cell Biol 120(2):371–383PubMed Nielsen S, Smith BL, Christensen EI, Knepper MA, Agre P (1993) CHIP28 water channels are localized in constitutively water-permeable segments of the nephron. J Cell Biol 120(2):371–383PubMed
14.
go back to reference Christensen S, Ottosen PD (1983) Lithium-induced uremia in rats—a new model of chronic renal failure. Pflugers Arch 399(3):208–212PubMed Christensen S, Ottosen PD (1983) Lithium-induced uremia in rats—a new model of chronic renal failure. Pflugers Arch 399(3):208–212PubMed
15.
go back to reference Regan RF, Guo Y (2001) Magnesium deprivation decreases cellular reduced glutathione and causes oxidative neuronal death in murine cortical cultures. Brain Res 890(1):177–183PubMed Regan RF, Guo Y (2001) Magnesium deprivation decreases cellular reduced glutathione and causes oxidative neuronal death in murine cortical cultures. Brain Res 890(1):177–183PubMed
16.
go back to reference Bussiere FI, Gueux E, Rock E, Mazur A, Rayssiguier Y (2002) Protective effect of calcium deficiency on the inflammatory response in magnesium-deficient rats. Eur J Nutr 41(5):197–202PubMed Bussiere FI, Gueux E, Rock E, Mazur A, Rayssiguier Y (2002) Protective effect of calcium deficiency on the inflammatory response in magnesium-deficient rats. Eur J Nutr 41(5):197–202PubMed
17.
go back to reference Bussiere FI, Gueux E, Rock E, Girardeau JP, Tridon A, Mazur A et al (2002) Increased phagocytosis and production of reactive oxygen species by neutrophils during magnesium deficiency in rats and inhibition by high magnesium concentration. Br J Nutr 87(2):107–113PubMed Bussiere FI, Gueux E, Rock E, Girardeau JP, Tridon A, Mazur A et al (2002) Increased phagocytosis and production of reactive oxygen species by neutrophils during magnesium deficiency in rats and inhibition by high magnesium concentration. Br J Nutr 87(2):107–113PubMed
18.
go back to reference Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M (2002) Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch Pharmacol 365(4):277–283PubMed Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M (2002) Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. Naunyn Schmiedebergs Arch Pharmacol 365(4):277–283PubMed
19.
go back to reference Ecelbarger CA, Sands JM, Doran JJ, Cacini W, Kishore BK (2001) Expression of salt and urea transporters in rat kidney during cisplatin-induced polyuria. Kidney Int 60(6):2274–2282PubMed Ecelbarger CA, Sands JM, Doran JJ, Cacini W, Kishore BK (2001) Expression of salt and urea transporters in rat kidney during cisplatin-induced polyuria. Kidney Int 60(6):2274–2282PubMed
20.
go back to reference Kjeldsen K, Norgaard A (1987) Effect of magnesium depletion on 3H-ouabain binding site concentration in rat skeletal muscle. Magnesium 6(1):55–60PubMed Kjeldsen K, Norgaard A (1987) Effect of magnesium depletion on 3H-ouabain binding site concentration in rat skeletal muscle. Magnesium 6(1):55–60PubMed
21.
go back to reference Daugaard G, Rossing N, Rorth M (1988) Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21(2):163–167PubMed Daugaard G, Rossing N, Rorth M (1988) Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol 21(2):163–167PubMed
22.
go back to reference Lajer H, Bundgaard H, Secher NH, Hansen HH, Kjeldsen K, Daugaard G (2003) Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin. Br J Cancer 89(9):1633–1637PubMed Lajer H, Bundgaard H, Secher NH, Hansen HH, Kjeldsen K, Daugaard G (2003) Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin. Br J Cancer 89(9):1633–1637PubMed
Metadata
Title
Magnesium depletion enhances cisplatin-induced nephrotoxicity.
Authors
H. Lajer
M. Kristensen
H. H. Hansen
S. Nielsen
J. Frøkiær
L. F. Østergaard
S. Christensen
G. Daugaard
T. E. N. Jonassen
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-005-1010-7

Other articles of this Issue 5/2005

Cancer Chemotherapy and Pharmacology 5/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine